PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 12, 2009, Pages 2191-2197

  Cariou, Bertrand ^a,b,c   Ouguerram, Khadija ^a,b   Zaïr, Yassine ^a,b,c   Guerois, Raphael ^d   Langhi, Cédric ^a,b   Kourimate, Sanae ^a,b   Benoit, Isabelle ^a,b   Le May, Cédric ^a   Gayet, Constance ^a   Belabbas, Khaldia ^e   Dufernez, Fabienne ^e   Chétiveaux, Maud ^a,b   Tarugi, Patrizia ^g   Krempf, Michel ^a,b,c   Benlian, Pascale ^e,f   Costet, Philippe ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c L INSTITUT DU THORAX   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Hypobetalipoproteinemia; LDL; Mutation; PCSK9

Indexed keywords

APOLIPOPROTEIN B; INSULIN; LOW DENSITY LIPOPROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CATABOLISM; CONTROLLED STUDY; DAUGHTER; FAMILIAL HYPOBETALIPOPROTEINEMIA; FATTY LIVER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; LIVER FUNCTION; MALE; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; APOLIPOPROTEINS B; CHOLESTEROL, LDL; FEMALE; GENES, DOMINANT; HEPATOCYTES; HETEROZYGOTE; HUMANS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; HYPOBETALIPOPROTEINEMIAS; KINETICS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 73849114174     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.194191     Document Type: Article

References (31)

1. Tarugi P, Averna M, Di LE, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007;195:e19-e27.
2. Linton MF, Farese RV Jr, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993;34:521-541.
3. Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res. 2003;44:878-883.
4. Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholester-olaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci. 2005;42:515-545.
5. Fouchier SW, Sankatsing RR, Peter J, Castillo S, Pocovi M, Alonso R, Kastelein JJ, Defesche JC. High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent. J Med Genet. 2005;42:e23.
6. Costet P, Krempf M, Cariou B. PCSK9 and LDL cholesterol: Unravelling the target to design the bullet. Trends Biochem Sci. 2008;33:426-434.
7. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholes-terolemia. Nat Genet. 2003;34:154-156. (Pubitemid 36666925)
8. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, Junien C, Varret M, Boileau C, Benlian P, Rabes JP. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat. 2005;26:497.
9. Berge KE, Ose L, Leren TP. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. Arterioscler Thromb Vasc Biol. 2006;26:1094-1100.
10. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
11. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Molecular Characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-523.
12. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445-448.
13. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004;24:1448-1453.
14. Shinde UP, Liu JJ, Inouye M. Protein memory through altered folding mediated by intramolecular chaperones. Nature. 1997;389:520-522.
15. Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier JM, Ozenberger BA, Jacobsen JS, Kennedy JD, DiStefano PS, Wood A, Bingham B. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys. 2003;420:55-67.
16. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, Soutar AK. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005;14:1161-1169.
17. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG. The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: Functional consequences of natural mutations and post-translational modifications. J Biol Chem. 2006;281:30561-30572.
18. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, Miyata T. Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis. 2007;196: 29-36.
19. Fasano T, Cefalu AB, Di LE, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, Guardamagna O, Averna M, Tarugi P. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2007; 27:677-681.
20. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102:5374-5379.
21. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000;105:521-532.
22. Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J. A new method for measurement of total plasma PCSK9-Clinical applications. J Lipid Res. In press.
23. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Plasma levels of PCSK9 in a large multiethnic population. J Clin Endocrinol Metab. 2009;94:2537-2543.
24. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology. 1997;138: 3779-3786.
25. Smith PM, Cowan A, White BA. The low-density lipoprotein receptor is regulated by estrogen and forms a functional complex with the estrogen-regulated protein ezrin in pituitary GH3 somatolactotropes. Endocrinology. 2004;145:3075-3083.
26. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007;53:1814-1819.
27. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest. 2006;116:2995-3005.
28. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A. 1984;81:3204-3208.
29. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;30:685-694.
30. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther. 2003; 306:332-337.
31. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest. 2006;116:581-589.